Somerilo

VISION & ROADMAP

Genetics first.
Progress through evidence.

Product development and institutional adoption, guided by validation evidence.

LONG-TERM VISION · NOT CURRENT FUNCTIONALITY

Coherent, traceable,
human-governed information.

A contextual intelligence direction for complex clinical workflows, beginning with genetics.

Read the full vision

PRODUCT ROADMAP

Each stage earns
the next decision.

Planning roadmap — progression depends on validation evidence and commercial learning.

  1. Phase 0Current

    Validation

    Functional Prototype · Validation Stage

    • Stabilize the core; evaluate technical and workflow fit
    • Gather user and buyer feedback
    • Test commercial hypotheses and measure product cost
    • Evaluate safety and governance

    Evidence gate: Go, Revise, or Stop / Re-scope.

  2. Phase 2Future direction

    Paid Institutional Pilots & Oman Commercialization

    Commercial direction

    • Test buyer willingness to pay through controlled pilots
    • Build repeatable implementation and institutional learning
    • Develop paying organizations and Oman commercialization

    Gate: pilot readiness and buyer evidence.

  3. Phase 3Future direction

    GCC Readiness & Regional Scale

    Regional ambition

    • Prepare enterprise delivery, integrations and localization
    • Explore selected partnerships and GCC opportunities

    GCC expansion remains a roadmap direction, rather than a current operating footprint.

  4. Phase 4Future direction

    Contextual Clinical Intelligence

    Long-term direction

    • Structured case information and richer evaluations
    • Evidence / provenance, integrations and expert collaboration
    • Additional complex clinical domains

    Gate: validation evidence and commercial learning.

COMMERCIALIZATION PATH

From validation
to repeatable deployment.

A commercial direction, separate from the product roadmap. Evidence informs progression between stages.

  1. 01
    PrototypeCurrent foundation
  2. 02
    ValidationCurrent stage
  3. 03
    Paid PilotIntended next step
  4. 04
    Repeatable Institutional DeploymentFuture direction
  5. 05
    Oman ScaleFuture direction
  6. 06
    GCCFuture direction
  7. 07
    Selected International MarketsFuture direction

Progression gate: demonstrated value, buyer learning and viable delivery economics.

COMMERCIAL MODEL

Designed around
institutional buyers.

These intended software and service mechanics are being validated.

Potential buyers include genetics laboratories and centres, hospitals and healthcare groups, genetics departments and referral networks.

  1. Paid Validation / Pilot

  2. Implementation & Configuration

  3. Annual Platform Licence

  4. AI & Infrastructure Usage

  5. Support / Managed Service / SLA

  6. Enterprise / Network Licensing

BEYOND ISOLATED AI INTERACTIONS

Designed for
institutional depth.

Long-term differentiation can develop through how the product supports continuing case information and institutional workflows.

Current
Conversation, documents, follow-up and evolving context.
Future direction
Structured information, evaluations, provenance, integration potential, governance and institutional deployment.

GENETICS-FIRST, NOT GENETICS-LIMITED

Depth today.
Careful extensibility over time.

Genetics is the first domain. Adjacent complex clinical domains remain future directions, subject to evidence and learning.

  • Hereditary / Rare DiseaseFuture direction
  • Precision HealthFuture direction
  • PharmacogenomicsFuture direction
  • Precision OncologyFuture direction
  • Other complex clinical domainsFuture direction

Start with a defined validation question.

Discuss a Validation Pilot